The Female Health Company Receives USAID-funded Order for 12 Million FC2 Units

CHICAGO, Sept. 8, 2009 (GLOBE NEWSWIRE) -- The Female Health Company
(Nasdaq:FHCO) announced that it has signed a contract with John Snow, Inc.(JSI),
for the supply of 12 million FC2 female condoms for HIV/AIDS prevention programs
supported by the U.S. Agency for International Development (USAID) in developing
countries worldwide. Under JSI, the USAID | DELIVER PROJECT will work to
increase the availability of essential health supplies to clients and customers
around the world.

For many years, USAID has been among one of the largest international donors of
contraceptives and condoms. The Agency developed an operational plan for its
HIV/AIDS "expanded response" strategy which includes the establishment of the
Commodity Fund (CF) to centrally-finance male and female condoms for HIV/AIDS
programs and to ensure their expedited delivery to countries. Through the
Commodity Fund and the President's Emergency Plan for AIDS Relief (PEPFAR),
USAID provides male and female condoms to Missions for HIV/AIDS prevention
activities.

O. B. Parrish, Chairman and CEO of FHC, praised USAID's actions stating, "In
continuing female condom procurement, USAID is demonstrating its commitment to
supporting HIV/AIDS prevention efforts around the world. This commitment is
particularly critical as the global community recognizes the increasing numbers
of females affected by AIDS." UNAIDS reports that worldwide, 33.2 million
people, 15.4 million of which are women aged 15 years and older, are now living
with HIV. The Global Coalition on Women and AIDS, a UNAIDS Initiative, is
calling for more money in AIDS programs that work for women including closing
the funding gap for the female condom and microbicides development."

About The Female Health Company

The Female Health Company (FHC), headquartered in Chicago, IL, is the maker of
the FC Female Condom (FC1 and FC2), a revolutionary option offering women dual
protection against both sexually transmitted diseases, including HIV/AIDS, and
unintended pregnancy. FHC was created as a worldwide company in February 1996
with the purchase of Chartex Resources Ltd., the holder of exclusive worldwide
rights to FC1. The Company holds exclusive product and technology patents for
FC1 in the United States, Australia, Brazil, Canada, France, Germany, Italy,
Spain, the United Kingdom, the People's Republic of China, South Korea and
Japan. FC2 patents have been granted in Australia, Canada and South Africa and
are pending in various other countries. FHC is the sole manufacturer and
marketer of the FC1 and FC2 female condoms in the world. The Female Health
Company and its partners currently market the Female Condom under FCFemale
Condom(r), FC2 Female Condom(r), Reality(r), Femidom(r), Femy(r), and Care(r).

Safe Harbor" statement under the Private Securities Litigation Reform Action of
1995:

The statements in this release which are not historical facts are
forward-looking statements based upon the Company's current plans and
strategies, and reflect the Company's current assessment of the risks and
uncertainties related to its business, including such things as product demand
and market acceptance; the economic and business environment and the impact of
government pressures; currency risks; capacity; efficiency and supply
constraints; and other risks detailed in the Company's press releases,
shareholder communications and Securities and Exchange Commission filings.
Actual events affecting the Company and the impact of such events on the
Company's operations may vary from those currently anticipated.

For more information about the Female Health Company visit the Company's web
site at www.femalehealthcompany.com

If you would like to be added to an e-mail alert list, please send an e-mail to
FHCInvestor@femalehealthcompany.com

-0-
CONTACT: The Female Health Company
William R. Gargiulo, Jr.
231.526.1244
Donna Felch
312.595.9123